KRAS and neoplasm: The median PFS was 1.64 months (95% CI = 0.46–4.37 months) for patients with plasma KRAS mutations only (pMUT-tWT) and 10.95 months (95% CI = 2.79–25.58 months) in patients with tumor tissue mutations only (pWT-tMUT).